| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $3,415,341 | 6 | 55 |
Sells | $279,010 | 5 | 45 |
| Lappe Mark | Chief Executive Officer | 3 | $1.85M | 0 | $0 | $1.85M |
| Kayyem Jon Faiz | director | 3 | $1.57M | 0 | $0 | $1.57M |
| MANHARD KIMBERLY | director | 0 | $0 | 5 | $279,010 | $-279,010 |
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is …
Over the last 12 months, insiders at Inhibrx Biosciences Inc. have bought $3.42M and sold $279,010 worth of Inhibrx Biosciences Inc. stock.
On average, over the past 5 years, insiders at Inhibrx Biosciences Inc. have bought $11.12M and sold $6.67M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Lappe Mark (Chief Executive Officer) — $1.85M. Kayyem Jon Faiz (director) — $1.57M.
The last purchase of 10,040 shares for transaction amount of $848,977 was made by Lappe Mark (Chief Executive Officer) on 2026‑10‑14.
| 2026-10-14 | Lappe Mark | Chief Executive Officer | 10,040 0.0677% | $84.56 | $848,977 | +5.34% | ||
| 2026-09-28 | Lappe Mark | Chief Executive Officer | 4,500 0.0285% | $100.76 | $453,426 | -8.50% | ||
| 2026-09-25 | Lappe Mark | Chief Executive Officer | 5,500 0.0349% | $99.16 | $545,357 | -6.27% | ||
| 2026-09-23 | Kayyem Jon Faiz | director | 5,000 0.034% | $100.00 | $500,000 | -6.93% | ||
| 2026-09-16 | Kayyem Jon Faiz | director | 5,000 0.0335% | $100.00 | $500,000 | -6.86% | ||
| 2026-09-15 | Sale | MANHARD KIMBERLY | director | 500 0.0034% | $105.05 | $52,525 | -10.04% | |
| 2026-09-14 | Sale | MANHARD KIMBERLY | director | 500 0.0032% | $110.26 | $55,130 | -13.86% | |
| 2026-09-11 | Sale | MANHARD KIMBERLY | director | 500 0.0033% | $111.78 | $55,888 | -12.78% | |
| 2026-09-09 | Sale | MANHARD KIMBERLY | director | 500 0.0035% | $115.80 | $57,898 | -15.24% | |
| 2026-09-08 | Sale | MANHARD KIMBERLY | director | 500 0.0032% | $115.14 | $57,570 | -15.76% | |
| 2026-09-08 | Kayyem Jon Faiz | director | 5,000 0.0317% | $113.52 | $567,580 | -15.76% | ||
| 2025-10-07 | Sale | VIKING GLOBAL INVESTORS LP | 10 percent owner | 350,000 2.3261% | $32.25 | $11.29M | +149.73% | |
| 2024-11-20 | Kayyem Jon Faiz | director | 18,750 0.1292% | $14.19 | $266,102 | +5.59% | ||
| 2024-11-19 | Kayyem Jon Faiz | director | 34,843 0.2402% | $14.23 | $495,708 | +3.39% | ||
| 2024-10-03 | Vuori Kristiina MD | director | 6,667 0.0451% | $15.00 | $100,005 | -1.38% | ||
| 2024-09-16 | Lappe Mark | Chief Executive Officer | 13,037 0.0885% | $17.13 | $223,324 | -15.81% | ||
| 2024-09-12 | Lappe Mark | Chief Executive Officer | 26,963 0.1859% | $15.05 | $405,793 | -2.69% | ||
| 2024-09-11 | Vuori Kristiina MD | director | 6,457 0.0443% | $15.07 | $97,307 | -2.17% | ||
| 2024-09-10 | Lappe Mark | Chief Executive Officer | 8,500 0.0588% | $15.19 | $129,115 | -3.33% | ||
| 2024-09-10 | Vuori Kristiina MD | director | 179 0.0012% | $15.00 | $2,685 | -3.33% |
| Lappe Mark | Chief Executive Officer | 745588 5.0659% | $60.45M | 8 | 6 | <0.0001% |
| Kayyem Jon Faiz | director | 434360 2.9513% | $35.22M | 5 | 4 | +4.49% |
| Shabet Rose Sharon | director | 2427307 16.4925% | $196.81M | 1 | 0 | <0.0001% |
| VIKING GLOBAL INVESTORS LP | 10 percent owner | 67018 0.4554% | $5.43M | 4 | 1 | +25.58% |
| Vuori Kristiina MD | director | 20443 0.1389% | $1.66M | 3 | 0 | <0.0001% |
$831,902,292 | 108 | 9.34% | $1.2B | |
$15,410,062 | 81 | 39.69% | $975.93M | |
$11,663,618 | 57 | 32.20% | $934.29M | |
$4,431,947 | 22 | 36.10% | $1.46B | |
$135,656,796 | 20 | 30.67% | $1.43B |
| Increased Positions | 83 | +74.77% | 3M | +33.05% |
| Decreased Positions | 47 | -42.34% | 1M | -11.04% |
| New Positions | 45 | New | 1M | New |
| Sold Out Positions | 10 | Sold Out | 259,839 | Sold Out |
| Total Postitions | 147 | +32.43% | 13M | +22.01% |
| Viking Global Investors Lp | $134,149.00 | 11.92% | 1.79M | 0 | 0% | 2025-09-30 |
| Perceptive Advisors Llc | $99,631.00 | 8.85% | 1.33M | +349,815 | +35.77% | 2025-09-30 |
| Sanofi | $86,891.00 | 7.72% | 1.16M | 0 | 0% | 2025-09-30 |
| Hightower Advisors, Llc | $65,417.00 | 5.81% | 871,759 | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $51,383.00 | 4.57% | 684,746 | -43,998 | -6.04% | 2025-09-30 |
| Vanguard Group Inc | $44,643.00 | 3.97% | 594,918 | -3,530 | -0.59% | 2025-09-30 |
| Morgan Stanley | $33,232.00 | 2.95% | 442,856 | +415,048 | +1,492.55% | 2025-09-30 |
| Sofinnova Investments, Inc. | $33,025.00 | 2.93% | 440,092 | -268,586 | -37.9% | 2025-09-30 |
| Woodline Partners Lp | $25,258.00 | 2.24% | 336,590 | -326,278 | -49.22% | 2025-09-30 |
| Millennium Management Llc | $22,348.00 | 1.99% | 297,820 | +22,042 | +7.99% | 2025-09-30 |